Robin Swartz - 10 Feb 2026 Form 4 Insider Report for Voyager Therapeutics, Inc. (VYGR)

Role: COO & CBO
Signature: /s/ Gregory Shiferman, as Attorney-in-Fact for Robin Swartz
Issuer symbol: VYGR
Transactions as of: 10 Feb 2026
Net transactions value: -$17,591
Form type: 4
Filing time: 11 Feb 2026, 16:32:27 UTC
Previous filing: 10 Feb 2026
Next filing: 20 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Swartz Robin	COO & CBO	C/O VOYAGER THERAPEUTICS, INC., 75 HAYDEN AVENUE, LEXINGTON	/s/ Gregory Shiferman, as Attorney-in-Fact for Robin Swartz	11 Feb 2026	0001909636

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VYGR	Common Stock	Sale	$17,591	-4,569	-2.1%	$3.85	210,078	10 Feb 2026	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2026. The sales do not represent a discretionary trade by the reporting person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.72 to $3.90, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Content

Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2026. The sales do not represent a discretionary trade by the reporting person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.72 to $3.90, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.